抗てんかん薬、双極性障害治療薬「ラミクタール錠」投与患者における重篤な皮膚障害に関する注意喚起について｜厚生労働省
https://www.mhlw.go.jp/stf/houdou/0000073061.htmlThe evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.
抗てんかん薬、双極性障害治療薬「ラミクタール錠」投与患者における重篤な皮膚障害に関する注意喚起について｜厚生労働省
Open the archived HTML with saved-time metadata attached.
This HTML has CSS and images embedded, so it can still be opened even if the original page disappears.
This page announces safety warnings from Japan's Ministry of Health, Labour and Welfare regarding "Lamictal tablets," an anti-epileptic and bipolar disorder treatment drug. As of February 4, 2015, four fatal cases of severe skin disorders were reported in patients who received doses exceeding the prescribed dosage. The incidence of skin disorders is significantly higher when dosage instructions are not followed, particularly in children. Healthcare providers are directed to ensure strict adherence to prescribed dosages, recommend early dermatological consultation for rash development, and discontinue medication if symptoms worsen. Patients are advised to immediately consult physicians upon experiencing initial symptoms such as rash or fever.
